Pluristem Therapeutics, Inc. (NASDAQ:PSTI) was the recipient of a significant growth in short interest in October. As of October 31st, there was short interest totalling 1,901,301 shares, a growth of 34.3% from the October 13th total of 1,415,640 shares. Based on an average trading volume of 1,120,080 shares, the short-interest ratio is currently 1.7 days. Approximately 2.2% of the company’s stock are short sold.
Shares of Pluristem Therapeutics (NASDAQ:PSTI) opened at $1.49 on Friday. Pluristem Therapeutics has a 12 month low of $1.04 and a 12 month high of $2.12.
Pluristem Therapeutics (NASDAQ:PSTI) last released its earnings results on Tuesday, November 14th. The biotechnology company reported ($0.08) earnings per share for the quarter, meeting the consensus estimate of ($0.08). analysts expect that Pluristem Therapeutics will post -0.34 earnings per share for the current year.
Several analysts recently issued reports on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $3.50 price target on shares of Pluristem Therapeutics in a report on Thursday, November 9th. Maxim Group reaffirmed a “buy” rating and issued a $2.00 price target on shares of Pluristem Therapeutics in a report on Tuesday, September 5th. ValuEngine raised shares of Pluristem Therapeutics from a “strong sell” rating to a “sell” rating in a report on Monday, October 2nd. Zacks Investment Research cut shares of Pluristem Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, September 22nd. Finally, Seaport Global Securities reaffirmed a “buy” rating and issued a $5.00 price target on shares of Pluristem Therapeutics in a report on Friday, October 6th. Two equities research analysts have rated the stock with a sell rating and four have given a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $4.38.
A number of hedge funds have recently added to or reduced their stakes in PSTI. Heritage Investors Management Corp bought a new stake in Pluristem Therapeutics during the third quarter valued at $113,000. Psagot Investment House Ltd. increased its stake in Pluristem Therapeutics by 1,705.2% during the third quarter. Psagot Investment House Ltd. now owns 129,522 shares of the biotechnology company’s stock valued at $196,000 after purchasing an additional 122,347 shares during the last quarter. Jane Street Group LLC increased its stake in Pluristem Therapeutics by 15.0% during the third quarter. Jane Street Group LLC now owns 266,043 shares of the biotechnology company’s stock valued at $402,000 after purchasing an additional 34,742 shares during the last quarter. Finally, Renaissance Technologies LLC increased its stake in Pluristem Therapeutics by 9.1% during the first quarter. Renaissance Technologies LLC now owns 1,553,800 shares of the biotechnology company’s stock valued at $1,911,000 after purchasing an additional 129,000 shares during the last quarter. Hedge funds and other institutional investors own 4.08% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Short Interest in Pluristem Therapeutics, Inc. (PSTI) Rises By 34.3%” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another website, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2017/11/18/short-interest-in-pluristem-therapeutics-inc-psti-rises-by-34-3.html.
About Pluristem Therapeutics
Pluristem Therapeutics Inc is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company’s lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome.
Receive News & Ratings for Pluristem Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.